Compare PRIM & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRIM | GPCR |
|---|---|---|
| Founded | 1960 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 3.8B |
| IPO Year | 2006 | 2023 |
| Metric | PRIM | GPCR |
|---|---|---|
| Price | $84.63 | $27.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 16 |
| Target Price | ★ $117.80 | $105.78 |
| AVG Volume (30 Days) | 1.1M | ★ 1.2M |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | ★ 0.38% | N/A |
| EPS Growth | ★ 51.66 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.32 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $65.00 | $25.59 |
| 52 Week High | $205.50 | $94.90 |
| Indicator | PRIM | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 66.47 | 17.84 |
| Support Level | $70.54 | N/A |
| Resistance Level | $85.60 | $56.63 |
| Average True Range (ATR) | 3.41 | 1.92 |
| MACD | 1.21 | -0.63 |
| Stochastic Oscillator | 82.87 | 5.99 |
Primoris Services Corp is a provider of critical infrastructure services operating mainly in the United States and Canada. The company provides a range of construction, maintenance, replacement, and engineering services. The Utilities segment operates throughout the United States and specializes in a range of services, including the construction and maintenance of new and existing natural gas and electric utility distribution and transmission systems, and communications systems. The Energy segment operates throughout the United States and Canada and specializes in a range of services that include engineering, procurement, construction, and maintenance services to various industries. The majority of the company's revenue is derived from the Energy segment.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.